<p>擁有大量資金的投資者對 <strong>再生元製藥</strong> (NASDAQ: REGN) 持樂觀態度。</p>
<p>而散户交易者應該知道這一點。</p>
<p>我們今天注意到這一點，當這些頭寸出現在我們在 Benzinga 跟蹤的公開可用期權歷史中。</p>
<p>我們不知道這些是機構還是僅僅是富有的個人。但當 REGN 發生如此重大的事情時，通常意味着有人知道即將發生什麼。</p>
<p>今天，Benzinga 的期權掃描儀發現了 13 筆 <strong>再生元製藥</strong> 的期權交易。</p>
<p>這並不正常。</p>
<p>這些大資金交易者的整體情緒在 38% 看漲和 30% 看跌之間分裂。</p>
<p>在我們發現的所有期權中，有 1 筆看跌期權，總金額為 56,100 美元，以及 12 筆看漲期權，總金額為 540,338 美元。</p>
<h3>價格目標是什麼？</h3>
<p>在評估交易量和未平倉合約後，很明顯主要市場參與者正關注 <strong>再生元製藥</strong> 的價格區間在 400.0 美元到 1000.0 美元之間，涵蓋了過去三個月。</p>
<h3>交易量與未平倉合約的洞察</h3>
<p>查看交易量和未平倉合約是交易期權時的一個強大舉措。這些數據可以幫助您跟蹤 <strong>再生元製藥</strong> 在特定行權價格的期權流動性和興趣。下面，我們可以觀察到過去 30 天內所有 <strong>再生元製藥</strong> 的鯨魚交易在 400.0 美元到 1000.0 美元的行權價格範圍內的交易量和未平倉合約的演變。</p>
<h3>再生元製藥過去 30 天的期權交易量和未平倉合約</h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766512900_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="期權看漲圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766512900_0.png"/></p>
<h3>檢測到的重要期權交易：</h3>
<table>
<thead>
<tr>
<th><strong>符號</strong></th>
<th><strong>看跌/看漲</strong></th>
<th><strong>交易類型</strong></th>
<th><strong>情緒</strong></th>
<th><strong>到期日</strong></th>
<th><strong>賣出價</strong></th>
<th><strong>買入價</strong></th>
<th><strong>價格</strong></th>
<th><strong>行權價格</strong></th>
<th><strong>總交易價格</strong></th>
<th align="right"><strong>未平倉合約</strong></th>
<th align="right"><strong>交易量</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>看漲</td>
<td>交易</td>
<td>中性</td>
<td>03/20/26</td>
<td>$134.6</td>
<td>$128.1</td>
<td>$131.5</td>
<td>$670.00</td>
<td>$78.9K</td>
<td align="right">11</td>
<td align="right">12</td>
</tr>
<tr>
<td>REGN</td>
<td>看跌</td>
<td>交易</td>
<td>看漲</td>
<td>03/20/26</td>
<td>$38.6</td>
<td>$37.2</td>
<td>$37.4</td>
<td>$760.00</td>
<td>$56.1K</td>
<td align="right">13</td>
<td align="right">17</td>
</tr>
<tr>
<td>REGN</td>
<td>看漲</td>
<td>交易</td>
<td>看跌</td>
<td>05/15/26</td>
<td>$60.0</td>
<td>$58.0</td>
<td>$58.0</td>
<td>$820.00</td>
<td>$52.2K</td>
<td align="right">137</td>
<td align="right">27</td>
</tr>
<tr>
<td>REGN</td>
<td>看漲</td>
<td>交易</td>
<td>看漲</td>
<td>01/15/27</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$1000.00</td>
<td>$49.0K</td>
<td align="right">108</td>
<td align="right">10</td>
</tr>
<tr>
<td>REGN</td>
<td>看漲</td>
<td>交易</td>
<td>看漲</td>
<td>03/20/26</td>
<td>$69.9</td>
<td>$66.5</td>
<td>$69.9</td>
<td>$760.00</td>
<td>$48.9K</td>
<td align="right">102</td>
<td align="right">7</td>
</tr>
</tbody>
</table>
<h3>關於再生元製藥</h3>
<p>再生元製藥發現、開發和商業化用於治療眼病、心血管疾病、癌症和炎症的產品。該公司有多個已上市產品，包括用於濕性年齡相關性黃斑變性和其他眼病的低劑量 Eylea 和 Eylea HD；在免疫學領域的 Dupixent；用於降低 LDL 膽固醇的 Praluent；在腫瘤學領域的 Libtayo；以及在類風濕關節炎領域的 Kevzara。再生元還與賽諾菲及其他合作伙伴獨立開發單克隆抗體和雙特異性抗體，並擁有早期階段的合作伙伴關係，將新技術引入管道，包括 RNAi（Alnylam）和基於 Crispr 的基因編輯（Intellia）。</p>
<p>在對圍繞再生元製藥的期權交易進行徹底審查後，我們將更詳細地審視該公司。這包括對其當前市場狀態和表現的評估。</p>
<h3>再生元製藥的當前市場地位</h3>
<ul>
<li>目前交易量為 246,591，REGN 的價格下跌了 -0.17%，現為 778.0 美元。</li>
<li>RSI 指標顯示該股票可能接近超買狀態。</li>
<li>預計收益發布將在 42 天后。</li>
</ul>
<h3>再生元製藥的專業分析師評級</h3>
<p>在過去 30 天內，共有 5 位專業分析師對該股票進行了評估，設定的平均價格目標為 786.2 美元。</p>
<p><strong>檢測到異常期權活動：聰明資金在行動</strong></p>
<p>Benzinga Edge 的異常期權板塊在潛在市場動向發生之前發現可能的市場推動者。查看大資金在您喜歡的股票上採取了什麼頭寸。點擊這裏訪問。
* 反映出擔憂，Truist Securities 的一位分析師將其評級下調至買入，新的價格目標為 798 美元。
* 在評估中保持一致，Scotiabank 的一位分析師對再生元製藥保持行業表現評級，目標價格為 770 美元。
* Wells Fargo 的一位分析師繼續對再生元製藥保持等權重評級，目標價格為 745 美元。
* BMO Capital 的一位分析師繼續對再生元製藥保持跑贏大盤評級，目標價格為 850 美元。
* 摩根士丹利的一位分析師繼續對再生元製藥保持等權重評級，目標價格為 768 美元。</p>
<p>期權交易存在更高的風險和潛在的回報。精明的交易者通過不斷學習、調整策略、監控多個指標以及密切關注市場動態來管理這些風險。通過來自 Benzinga Pro 的實時警報，隨時瞭解最新的再生元製藥期權交易。</p>

再生元制藥

<p>投資者對再生元製藥表現出興趣，檢測到顯著的期權活動。市場情緒混合，38% 看漲，30% 看跌。主要市場動向集中在 400 美元到 1000 美元的價格區間。分析師的評級各不相同，價格目標範圍在 745 美元到 850 美元之間。該股票目前交易價格為 778 美元，下跌 0.17%。期權交易帶來更高的風險和回報，需要仔細監控和策略調整</p>

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Regeneron Pharmaceuticals</strong> (NASDAQ: REGN).</p>
<div class="lb-trans"><p>擁有大量資金的投資者對 <strong>再生元製藥</strong> (NASDAQ: REGN) 持樂觀態度。</p>
</div><p>And retail traders should know.</p>
<div class="lb-trans"><p>而散户交易者應該知道這一點。</p>
</div><p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<div class="lb-trans"><p>我們今天注意到這一點，當這些頭寸出現在我們在 Benzinga 跟蹤的公開可用期權歷史中。</p>
</div><p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with REGN, it often means somebody knows something is about to happen.</p>
<div class="lb-trans"><p>我們不知道這些是機構還是僅僅是富有的個人。但當 REGN 發生如此重大的事情時，通常意味着有人知道即將發生什麼。</p>
</div><p>Today, Benzinga's options scanner spotted 13 options trades for <strong>Regeneron Pharmaceuticals</strong>.</p>
<div class="lb-trans"><p>今天，Benzinga 的期權掃描儀發現了 13 筆 <strong>再生元製藥</strong> 的期權交易。</p>
</div><p>This isn't normal.</p>
<div class="lb-trans"><p>這並不正常。</p>
</div><p>The overall sentiment of these big-money traders is split between 38% bullish and 30%, bearish.</p>
<div class="lb-trans"><p>這些大資金交易者的整體情緒在 38% 看漲和 30% 看跌之間分裂。</p>
</div><p>Out of all of the options we uncovered, there was 1 put, for a total amount of $56,100, and 12, calls, for a total amount of $540,338.</p>
<div class="lb-trans"><p>在我們發現的所有期權中，有 1 筆看跌期權，總金額為 56,100 美元，以及 12 筆看漲期權，總金額為 540,338 美元。</p>
</div><h3>What's The Price Target?</h3>
<div class="lb-trans"><h3>價格目標是什麼？</h3>
</div><p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $400.0 and $1000.0 for Regeneron Pharmaceuticals, spanning the last three months.</p>
<div class="lb-trans"><p>在評估交易量和未平倉合約後，很明顯主要市場參與者正關注 <strong>再生元製藥</strong> 的價格區間在 400.0 美元到 1000.0 美元之間，涵蓋了過去三個月。</p>
</div><h3>Insights into Volume &amp; Open Interest</h3>
<div class="lb-trans"><h3>交易量與未平倉合約的洞察</h3>
</div><p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Regeneron Pharmaceuticals's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Regeneron Pharmaceuticals's whale trades within a strike price range from $400.0 to $1000.0 in the last 30 days.</p>
<div class="lb-trans"><p>查看交易量和未平倉合約是交易期權時的一個強大舉措。這些數據可以幫助您跟蹤 <strong>再生元製藥</strong> 在特定行權價格的期權流動性和興趣。下面，我們可以觀察到過去 30 天內所有 <strong>再生元製藥</strong> 的鯨魚交易在 400.0 美元到 1000.0 美元的行權價格範圍內的交易量和未平倉合約的演變。</p>
</div><h3>Regeneron Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<div class="lb-trans"><h3>再生元製藥過去 30 天的期權交易量和未平倉合約</h3>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766512900_0.png" alt="Options Call Chart" original-src="https://www.benzinga.com/files/images/story/2025/1766512900_0.png"/></p>
<h3>Significant Options Trades Detected:</h3>
<div class="lb-trans"><h3>檢測到的重要期權交易：</h3>
</div><table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/20/26</td>
<td>$134.6</td>
<td>$128.1</td>
<td>$131.5</td>
<td>$670.00</td>
<td>$78.9K</td>
<td align="right">11</td>
<td align="right">12</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$38.6</td>
<td>$37.2</td>
<td>$37.4</td>
<td>$760.00</td>
<td>$56.1K</td>
<td align="right">13</td>
<td align="right">17</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/15/26</td>
<td>$60.0</td>
<td>$58.0</td>
<td>$58.0</td>
<td>$820.00</td>
<td>$52.2K</td>
<td align="right">137</td>
<td align="right">27</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$1000.00</td>
<td>$49.0K</td>
<td align="right">108</td>
<td align="right">10</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$69.9</td>
<td>$66.5</td>
<td>$69.9</td>
<td>$760.00</td>
<td>$48.9K</td>
<td align="right">102</td>
<td align="right">7</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>符號</strong></th>
<th><strong>看跌/看漲</strong></th>
<th><strong>交易類型</strong></th>
<th><strong>情緒</strong></th>
<th><strong>到期日</strong></th>
<th><strong>賣出價</strong></th>
<th><strong>買入價</strong></th>
<th><strong>價格</strong></th>
<th><strong>行權價格</strong></th>
<th><strong>總交易價格</strong></th>
<th align="right"><strong>未平倉合約</strong></th>
<th align="right"><strong>交易量</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>看漲</td>
<td>交易</td>
<td>中性</td>
<td>03/20/26</td>
<td>$134.6</td>
<td>$128.1</td>
<td>$131.5</td>
<td>$670.00</td>
<td>$78.9K</td>
<td align="right">11</td>
<td align="right">12</td>
</tr>
<tr>
<td>REGN</td>
<td>看跌</td>
<td>交易</td>
<td>看漲</td>
<td>03/20/26</td>
<td>$38.6</td>
<td>$37.2</td>
<td>$37.4</td>
<td>$760.00</td>
<td>$56.1K</td>
<td align="right">13</td>
<td align="right">17</td>
</tr>
<tr>
<td>REGN</td>
<td>看漲</td>
<td>交易</td>
<td>看跌</td>
<td>05/15/26</td>
<td>$60.0</td>
<td>$58.0</td>
<td>$58.0</td>
<td>$820.00</td>
<td>$52.2K</td>
<td align="right">137</td>
<td align="right">27</td>
</tr>
<tr>
<td>REGN</td>
<td>看漲</td>
<td>交易</td>
<td>看漲</td>
<td>01/15/27</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$1000.00</td>
<td>$49.0K</td>
<td align="right">108</td>
<td align="right">10</td>
</tr>
<tr>
<td>REGN</td>
<td>看漲</td>
<td>交易</td>
<td>看漲</td>
<td>03/20/26</td>
<td>$69.9</td>
<td>$66.5</td>
<td>$69.9</td>
<td>$760.00</td>
<td>$48.9K</td>
<td align="right">102</td>
<td align="right">7</td>
</tr>
</tbody>
</table>
</div><h3>About Regeneron Pharmaceuticals</h3>
<div class="lb-trans"><h3>關於再生元製藥</h3>
</div><p>Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).</p>
<div class="lb-trans"><p>再生元製藥發現、開發和商業化用於治療眼病、心血管疾病、癌症和炎症的產品。該公司有多個已上市產品，包括用於濕性年齡相關性黃斑變性和其他眼病的低劑量 Eylea 和 Eylea HD；在免疫學領域的 Dupixent；用於降低 LDL 膽固醇的 Praluent；在腫瘤學領域的 Libtayo；以及在類風濕關節炎領域的 Kevzara。再生元還與賽諾菲及其他合作伙伴獨立開發單克隆抗體和雙特異性抗體，並擁有早期階段的合作伙伴關係，將新技術引入管道，包括 RNAi（Alnylam）和基於 Crispr 的基因編輯（Intellia）。</p>
</div><p>After a thorough review of the options trading surrounding Regeneron Pharmaceuticals, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<div class="lb-trans"><p>在對圍繞再生元製藥的期權交易進行徹底審查後，我們將更詳細地審視該公司。這包括對其當前市場狀態和表現的評估。</p>
</div><h3>Present Market Standing of Regeneron Pharmaceuticals</h3>
<div class="lb-trans"><h3>再生元製藥的當前市場地位</h3>
</div><ul>
<li>Currently trading with a volume of 246,591, the REGN's price is down by -0.17%, now at $778.0.</li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 42 days.</li>
</ul>
<div class="lb-trans"><ul>
<li>目前交易量為 246,591，REGN 的價格下跌了 -0.17%，現為 778.0 美元。</li>
<li>RSI 指標顯示該股票可能接近超買狀態。</li>
<li>預計收益發布將在 42 天后。</li>
</ul>
</div><h3>Professional Analyst Ratings for Regeneron Pharmaceuticals</h3>
<div class="lb-trans"><h3>再生元製藥的專業分析師評級</h3>
</div><p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $786.2.</p>
<div class="lb-trans"><p>在過去 30 天內，共有 5 位專業分析師對該股票進行了評估，設定的平均價格目標為 786.2 美元。</p>
</div><p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<div class="lb-trans"><p><strong>檢測到異常期權活動：聰明資金在行動</strong></p>
</div><p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.
* Reflecting concerns, an analyst from Truist Securities lowers its rating to Buy with a new price target of $798.
* Consistent in their evaluation, an analyst from Scotiabank keeps a Sector Perform rating on Regeneron Pharmaceuticals with a target price of $770.
* An analyst from Wells Fargo persists with their Equal-Weight rating on Regeneron Pharmaceuticals, maintaining a target price of $745.
* Maintaining their stance, an analyst from BMO Capital continues to hold a Outperform rating for Regeneron Pharmaceuticals, targeting a price of $850.
* Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for Regeneron Pharmaceuticals, targeting a price of $768.</p>
<div class="lb-trans"><p>Benzinga Edge 的異常期權板塊在潛在市場動向發生之前發現可能的市場推動者。查看大資金在您喜歡的股票上採取了什麼頭寸。點擊這裏訪問。
* 反映出擔憂，Truist Securities 的一位分析師將其評級下調至買入，新的價格目標為 798 美元。
* 在評估中保持一致，Scotiabank 的一位分析師對再生元製藥保持行業表現評級，目標價格為 770 美元。
* Wells Fargo 的一位分析師繼續對再生元製藥保持等權重評級，目標價格為 745 美元。
* BMO Capital 的一位分析師繼續對再生元製藥保持跑贏大盤評級，目標價格為 850 美元。
* 摩根士丹利的一位分析師繼續對再生元製藥保持等權重評級，目標價格為 768 美元。</p>
</div><p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Regeneron Pharmaceuticals options trades with real-time alerts from Benzinga Pro.</p>
<div class="lb-trans"><p>期權交易存在更高的風險和潛在的回報。精明的交易者通過不斷學習、調整策略、監控多個指標以及密切關注市場動態來管理這些風險。通過來自 Benzinga Pro 的實時警報，隨時瞭解最新的再生元製藥期權交易。</p>
</div>

再生元製藥的期權狂潮：你需要了解的內容